Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's Disease.
Behaviour
Diffusion kurtosis imaging
MRI
Methamphetamine
Mice
Parkinson’s disease
Tract-based spatial statistics
Journal
Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
22
10
2018
accepted:
28
05
2019
revised:
24
05
2019
pubmed:
19
6
2019
medline:
19
5
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
Methamphetamine (METH) abuse is known to increase the risk of Parkinson's disease (PD) due to its dopaminergic neurotoxicity. This is the rationale for the METH model of PD developed by toxic METH dosing (10 mg/kg four times every 2 h) which features robust neurodegeneration and typical motor impairment in mice. In this study, we used diffusion kurtosis imaging to reveal microstructural brain changes caused by METH-induced neurodegeneration. The METH-treated mice and saline-treated controls underwent diffusion kurtosis imaging scanning using the Bruker Avance 9.4 Tesla MRI system at two time-points: 5 days and 1 month to capture both early and late changes induced by METH. At 5 days, we found a decrease in kurtosis in substantia nigra, striatum and sensorimotor cortex, which is likely to indicate loss of DAergic neurons. At 1 month, we found an increase of kurtosis in striatum and sensorimotor cortex and hippocampus, which may reflect certain recovery processes. Furthermore, we performed tract-based spatial statistics analysis in the white matter and at 1 month, we observed increased kurtosis in ventral nucleus of the lateral lemniscus and some of the lateral thalamic nuclei. No changes were present at the early stage. This study confirms the ability of diffusion kurtosis imaging to detect microstructural pathological processes in both grey and white matter in the METH model of PD. The exact mechanisms underlying the kurtosis changes remain to be elucidated but kurtosis seems to be a valuable biomarker for tracking microstructural brain changes in PD and potentially other neurodegenerative disorders.
Identifiants
pubmed: 31209787
doi: 10.1007/s12640-019-00068-0
pii: 10.1007/s12640-019-00068-0
doi:
Substances chimiques
Dopamine Agents
0
Methamphetamine
44RAL3456C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
724-735Subventions
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : MUNI/A/1550/2018
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LM2015062
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : CZ.1.05/2.1.00/01.0017
Organisme : European Regional Development Fund
ID : No. CZ.02.1.01/0.0/0.0/16_013/0001775
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy (CZ)
ID : RVO:68081731
Organisme : Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (HU)
ID : 2017-1.2.1-NKP-2017-00002
Organisme : EFOP
ID : EFOP-3.6.1-16-2016-00008
Organisme : Országos Tudományos Kutatási Alapprogramok
ID : KTIA_13_NAP-A-II/20
Organisme : Masarykova Univerzita
ID : Junior Scientist Support Project
Commentaires et corrections
Type : CommentIn
Références
Prog Neurobiol. 2017 Aug;155:149-170
pubmed: 26455459
Neurotoxicology. 2006 Jan;27(1):131-6
pubmed: 16165214
Brain Res. 2000 Jul 21;871(2):259-70
pubmed: 10899292
Brain Res Bull. 2018 May;139:91-98
pubmed: 29378223
Neurotherapeutics. 2012 Apr;9(2):297-314
pubmed: 22350713
FEBS Lett. 2012 Sep 21;586(19):3222-8
pubmed: 22771474
Neurotherapeutics. 2007 Jul;4(3):316-29
pubmed: 17599699
Neuropsychopharmacology. 2005 Jun;30(6):1128-37
pubmed: 15688084
Ann N Y Acad Sci. 1997 May 30;820:123-38
pubmed: 9237452
Neuroscience. 2006 Nov 3;142(4):1245-53
pubmed: 16934409
CMAJ. 2016 Nov 1;188(16):1157-1165
pubmed: 27221269
J Neurosci. 2001 Dec 1;21(23):9414-8
pubmed: 11717374
Neuroimage. 2016 Nov 15;142:421-430
pubmed: 27389790
NMR Biomed. 2017 Nov;30(11):
pubmed: 28841758
Neuroimage. 2015 Nov 1;121:20-8
pubmed: 26208874
Neuroscience. 2014 Sep 26;277:647-64
pubmed: 25090921
Brain Res. 1986 Feb 12;365(1):15-20
pubmed: 3947981
Ann N Y Acad Sci. 2008 Oct;1139:345-9
pubmed: 18991880
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a009316
pubmed: 22229125
Trends Neurosci. 1996 Aug;19(8):312-8
pubmed: 8843599
Neurotox Res. 2015 Nov;28(4):281-9
pubmed: 26153486
Brain Res Bull. 2005 May 15;65(5):405-13
pubmed: 15833595
Brain Behav Immun. 2017 Mar;61:197-208
pubmed: 27923670
Brain Res Rev. 2008 Jun;58(1):192-208
pubmed: 18440072
Hum Brain Mapp. 2017 Jul;38(7):3704-3722
pubmed: 28470878
Brain Res. 1996 Oct 28;738(1):172-5
pubmed: 8949944
JAMA. 2011 Aug 24;306(8):814
pubmed: 21862738
J Neurosci. 2004 Oct 20;24(42):9434-40
pubmed: 15496679
PLoS One. 2013;8(3):e59032
pubmed: 23516593
Med Image Anal. 2001 Jun;5(2):143-56
pubmed: 11516708
Hum Brain Mapp. 2002 Nov;17(3):143-55
pubmed: 12391568
J Neurosci Methods. 2003 Mar 15;123(2):189-200
pubmed: 12606067
Neurology. 2009 Apr 21;72(16):1378-84
pubmed: 19129507
Neuroradiology. 2014 Mar;56(3):251-8
pubmed: 24468858
J Neuroimaging. 2007 Apr;17 Suppl 1:27S-30S
pubmed: 17425731
J Neurosci. 2004 Jun 30;24(26):6028-36
pubmed: 15229250
Front Syst Neurosci. 2015 Mar 24;9:43
pubmed: 25852500
J Adv Pharm Technol Res. 2016 Oct-Dec;7(4):123-126
pubmed: 27833890
J Pharmacol Exp Ther. 1992 Nov;263(2):617-26
pubmed: 1432692
Neuroimage. 2006 Jul 15;31(4):1487-505
pubmed: 16624579
Drug Alcohol Depend. 2018 Jun 1;187:134-140
pubmed: 29665491
J Pharmacol Exp Ther. 1997 Aug;282(2):834-8
pubmed: 9262348
Ann N Y Acad Sci. 2008 Oct;1139:127-39
pubmed: 18991857
Radiology. 2011 Oct;261(1):210-7
pubmed: 21771952
Neurotox Res. 2009 Aug;16(2):127-39
pubmed: 19526289
Mol Neurodegener. 2009 Nov 16;4:47
pubmed: 19917131
Neuroimage Clin. 2013 Oct 14;3:481-8
pubmed: 24273730
Magn Reson Med. 2000 Aug;44(2):283-91
pubmed: 10918328
Eur J Pharmacol. 2014 Dec 15;745:243-8
pubmed: 25445041
Brain Struct Funct. 2011 Jun;216(2):123-35
pubmed: 21225282
Neuroscience. 2008 Jan 24;151(2):533-43
pubmed: 18082974
Brain Res. 2014 Jun 27;1570:35-42
pubmed: 24833063
Magn Reson Med. 2009 Jun;61(6):1336-49
pubmed: 19319973
Neurotox Res. 2005 Nov;8(3-4):199-206
pubmed: 16371314
Food Funct. 2010 Oct;1(1):15-31
pubmed: 21776454
Parkinsons Dis. 2013;2013:308052
pubmed: 23476887
Neurobiol Dis. 2012 Feb;45(2):810-20
pubmed: 22115942
Neurotox Res. 2010 Jul;18(1):48-58
pubmed: 19760475
Neurotox Res. 2011 Aug;20(2):170-81
pubmed: 21104462
J Clin Neurosci. 2018 Apr;50:199-202
pubmed: 29366621
Ann N Y Acad Sci. 2008 Oct;1141:195-220
pubmed: 18991959
Radiology. 1996 Dec;201(3):637-48
pubmed: 8939209
Exp Neurol. 2007 Nov;208(1):1-25
pubmed: 17720159
J Neurol. 2011 Jul;258(7):1254-60
pubmed: 21287185
J Neurochem. 2005 Feb;92(4):790-7
pubmed: 15686480
Arch Gen Psychiatry. 2004 Jan;61(1):73-84
pubmed: 14706946
Eur J Neurol. 2008 Sep;15 Suppl 2:2-7
pubmed: 18702736
J Neurochem. 2016 Mar;136(6):1259-1269
pubmed: 26685006
NMR Biomed. 2010 Aug;23(7):698-710
pubmed: 20632416
Toxicol Lett. 2014 Oct 1;230(1):19-27
pubmed: 25090657
NMR Biomed. 1995 Nov-Dec;8(7-8):333-44
pubmed: 8739270
Front Hum Neurosci. 2014 Jul 22;8:537
pubmed: 25100979